Lexaria Bioscience Corp. (LEXX)
3.08
+0.09
(+3.01%)
USD |
NASDAQ |
Oct 23, 16:00
3.00
-0.08
(-2.60%)
After-Hours: 20:00
Lexaria Bioscience Enterprise Value : 1.165M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.165M |
| October 22, 2026 | 1.017M |
| October 21, 2026 | 0.7357M |
| October 20, 2026 | 0.4547M |
| October 19, 2026 | 0.3721M |
| October 16, 2026 | 0.8017M |
| October 15, 2026 | 1.017M |
| October 14, 2026 | 0.7357M |
| October 13, 2026 | 0.7026M |
| October 12, 2026 | 1.479M |
| October 09, 2026 | 1.562M |
| October 08, 2026 | 1.364M |
| October 07, 2026 | 1.793M |
| October 06, 2026 | 1.430M |
| October 05, 2026 | 0.653M |
| October 02, 2026 | 0.8348M |
| October 01, 2026 | 1.182M |
| September 30, 2026 | 1.281M |
| September 29, 2026 | 1.248M |
| September 28, 2026 | 1.405M |
| September 25, 2026 | 1.496M |
| September 24, 2026 | 1.644M |
| September 23, 2026 | 1.421M |
| September 22, 2026 | 1.397M |
| September 21, 2026 | 1.735M |
| Date | Value |
|---|---|
| September 18, 2026 | 1.430M |
| September 17, 2026 | 1.512M |
| September 16, 2026 | 1.190M |
| September 15, 2026 | 1.380M |
| September 14, 2026 | 1.942M |
| September 11, 2026 | 2.636M |
| September 10, 2026 | 2.768M |
| September 09, 2026 | 6.982M |
| September 08, 2026 | 11.56M |
| September 04, 2026 | 19.46M |
| September 03, 2026 | 16.43M |
| September 02, 2026 | 17.90M |
| September 01, 2026 | 16.69M |
| August 31, 2026 | 14.72M |
| August 28, 2026 | 13.18M |
| August 27, 2026 | 15.38M |
| August 26, 2026 | 14.32M |
| August 25, 2026 | 15.24M |
| August 24, 2026 | 13.49M |
| August 21, 2026 | 14.11M |
| August 20, 2026 | 14.70M |
| August 19, 2026 | 15.10M |
| August 18, 2026 | 15.11M |
| August 17, 2026 | 13.13M |
| August 14, 2026 | 11.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Target Group, Inc. (Canada) | 11.78M |
| InMed Pharmaceuticals, Inc. | 5.455M |
| XORTX Therapeutics, Inc. | 0.5983M |
| NervGen Pharma Corp. | 91.00M |
| Milestone Pharmaceuticals, Inc. | 51.92M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.993M |
| Total Expenses (Quarterly) | 1.991M |
| EPS Diluted (Quarterly) | -1.204 |
| Earnings Yield | -171.4% |
| Normalized Earnings Yield | -167.17 |